|Mycophenolate Mofetil (Cellcept)
Lung Transplant Media Stories
Research on New Treatments
Mycophenolate mofetil (MMF) in systemic sclerosis-associated interstitial lung disease (SSc-ILD). In this retrospective study, we reviewed the medical files of 10 patients with SSc-ILD and found that MMF stabilizes lung function of SSc-ILD after 12 months of treatment. Athanasios Koutroumpas. (SpringerLink) Clinical Rheumatology. 06/09/10. (Also see Cellcept)
Scleroderma Lung Study II. This study compares 2 different medications—daily oral cyclophosphamide (CYC, also called CytoxanTM) with daily oral mycophenolate mofetil (MMF, also called CellceptTM) in the treatment of scleroderma-related pulmonary fibrosis. There are twelve study centers across the U.S. University of California, Los Angeles. November 2009. (Also see Pulmonary Fibrosis, Cytoxan, and Clinical Trials)
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, Volunteer, or Donate.
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report or update any page content or links.
Toll Free US/Canada Scleroderma Hotline: 800-564-7099